Terms: = Germ cell tumor AND TRIM27, DASS-46L4_6, RFP, 5987, ENSG00000234495, RNF76 AND Clinical Outcome
705 results:
1. Frequency and characteristics of immune-related thyroid adverse events in patients with resected stage III/IV melanoma treated with adjuvant PD-1 inhibitors: a national cohort study.
Christensen SK; Winther ML; Laursen IJ; Madsen FS; Brink C; Brix TH; Ellebaek E; Svane IM; Hansen FS; Haslund C; Laursen OK; Schmidt H; Larsen ID; Bastholt L; Ruhlmann CH
Support Care Cancer; 2024 Apr; 32(5):281. PubMed ID: 38598052
[TBL] [Abstract] [Full Text] [Related]
2. Prognostic factors for relapse in patients with clinical stage I testicular non-seminoma: A nationwide, population-based cohort study.
Wagner T; Toft BG; Lauritsen J; Bandak M; Christensen IJ; Engvad B; Kreiberg M; Agerbæk M; Dysager L; Carus A; Rosenvilde JJ; Berney D; Daugaard G
Eur J Cancer; 2024 May; 202():114025. PubMed ID: 38531266
[TBL] [Abstract] [Full Text] [Related]
3. Simulating photodynamic therapy for the treatment of glioblastoma using Monte Carlo radiative transport.
Finlayson L; McMillan L; Suveges S; Steele D; Eftimie R; Trucu D; Brown CTA; Eadie E; Hossain-Ibrahim K; Wood K
J Biomed Opt; 2024 Feb; 29(2):025001. PubMed ID: 38322729
[TBL] [Abstract] [Full Text] [Related]
4. GammaTile
Yekula A; Gessler DJ; Ferreira C; Shah R; Reynolds M; Dusenbery K; Chen CC
J Neurooncol; 2024 Feb; 166(3):441-450. PubMed ID: 38281303
[TBL] [Abstract] [Full Text] [Related]
5. National multicentered retrospective review of clinical and intraoperative factors associated with the development of cerebellar mutism after pediatric posterior fossa tumor resection.
Kameda-Smith MM; Ragulojan M; Elliott C; Bliss L; Moore H; Sader N; Alsuwaihel M; Tso MK; Dakson A; Ajani O; Yarascavitch B; Fleming A; Mehta V; Aminnejad M; Farrokhyar F; Singh SK;
Childs Nerv Syst; 2024 May; 40(5):1339-1347. PubMed ID: 38279985
[TBL] [Abstract] [Full Text] [Related]
6. Molecular characteristics and improved survival prediction in a cohort of 2023 ependymomas.
Pohl LC; Leitheiser M; Obrecht D; Schweizer L; Wefers AK; Eckhardt A; Raffeld M; Sturm D; Pajtler KW; Rutkowski S; Fukuoka K; Ichimura K; Bockmayr M; Schüller U
Acta Neuropathol; 2024 Jan; 147(1):24. PubMed ID: 38265522
[TBL] [Abstract] [Full Text] [Related]
7. Treatment evaluation by volumetric segmentation in pediatric optic pathway glioma: evaluation of the effect of bevacizumab on intra-tumor components.
Bennebroek CA; Schouten CR; Montauban-van Swijndregt MC; Saeed P; Porro GL; Pott JWR; Dittrich ATM; Oostenbrink R; Schouten-van Meeteren AY; de Jong MC; de Graaf P
J Neurooncol; 2024 Jan; 166(1):79-87. PubMed ID: 38150061
[TBL] [Abstract] [Full Text] [Related]
8. PATIENT-RELATED FACTORS AND clinical MANAGEMENT outcomeS OF RETINOBLASTOMA IN CALABAR, NIGERIA.
Nkanga ED; Nlemadim AC; Arazi M; Nkanga DG; Duke RE; Fabian ID; Nkanga ED; Odey FA; Meremikwu MM
West Afr J Med; 2023 Dec; 40(12 Suppl 1):S36-S37. PubMed ID: 38070170
[TBL] [Abstract] [Full Text] [Related]
9. Intratumoural and systemic inflammation as predictors for treatment response in BRAF-mutated melanoma patients under targeted therapies.
Gambichler T; Iordanou M; Becker JC; Susok L
Melanoma Res; 2024 Feb; 34(1):80-83. PubMed ID: 37924529
[TBL] [Abstract] [Full Text] [Related]
10. Thyroid transcription factor-1 expression in lung neuroendocrine tumours: a gender-related biomarker?
La Salvia A; Siciliani A; Rinzivillo M; Verrico M; Baldelli R; Puliani G; Modica R; Zanata I; Persano I; Fanciulli G; Bassi M; Mancini M; Bellino S; Giannetta E; Ibrahim M; Panzuto F; Brizzi MP; Faggiano A
Endocrine; 2024 Feb; 83(2):519-526. PubMed ID: 37775725
[TBL] [Abstract] [Full Text] [Related]
11. Guadecitabine plus ipilimumab in unresectable melanoma: five-year follow-up and integrated multi-omic analysis in the phase 1b NIBIT-M4 trial.
Noviello TMR; Di Giacomo AM; Caruso FP; Covre A; Mortarini R; Scala G; Costa MC; Coral S; Fridman WH; Sautès-Fridman C; Brich S; Pruneri G; Simonetti E; Lofiego MF; Tufano R; Bedognetti D; Anichini A; Maio M; Ceccarelli M
Nat Commun; 2023 Sep; 14(1):5914. PubMed ID: 37739939
[TBL] [Abstract] [Full Text] [Related]
12. Prognostic Factors for Relapse in Patients With clinical Stage I Testicular Seminoma: A Nationwide, Population-Based Cohort Study.
Wagner T; Toft BG; Lauritsen J; Bandak M; Christensen IJ; Engvad B; Kreiberg M; Agerbæk M; Dysager L; Rosenvilde JJ; Berney D; Daugaard G
J Clin Oncol; 2024 Jan; 42(1):81-89. PubMed ID: 37683134
[TBL] [Abstract] [Full Text] [Related]
13. A single center case series of immune checkpoint inhibitor-induced type 1 diabetes mellitus, patterns of disease onset and long-term clinical outcome.
Marsiglio J; McPherson JP; Kovacsovics-Bankowski M; Jeter J; Vaklavas C; Swami U; Grossmann D; Erickson-Wayman A; Soares HP; Kerrigan K; Gibson B; Doherty JA; Hyngstrom J; Hardikar S; Hu-Lieskovan S
Front Immunol; 2023; 14():1229823. PubMed ID: 37671166
[TBL] [Abstract] [Full Text] [Related]
14. Molecular Features of Resected Melanoma Brain Metastases, clinical outcomes, and Responses to Immunotherapy.
Vasudevan HN; Delley C; Chen WC; Mirchia K; Pan S; Shukla P; Aabedi AA; Nguyen MP; Morshed RA; Young JS; Boreta L; Fogh SE; Nakamura JL; Theodosopoulos PV; Phillips J; Hervey-Jumper SL; Daras M; Pike L; Aghi MK; Tsai K; Raleigh DR; Braunstein SE; Abate AR
JAMA Netw Open; 2023 Aug; 6(8):e2329186. PubMed ID: 37589977
[TBL] [Abstract] [Full Text] [Related]
15. Emilin2 fosters vascular stability by promoting pericyte recruitment.
Fejza A; Camicia L; Carobolante G; Poletto E; Paulitti A; Schinello G; Di Siena E; Cannizzaro R; Iozzo RV; Baldassarre G; Andreuzzi E; Spessotto P; Mongiat M
Matrix Biol; 2023 Sep; 122():18-32. PubMed ID: 37579864
[TBL] [Abstract] [Full Text] [Related]
16. NR2F6, a new immune checkpoint that acts as a potential biomarker of immunosuppression and contributes to poor clinical outcome in human glioma.
Miftah H; Naji O; Ssi SA; Ghouzlani A; Lakhdar A; Badou A
Front Immunol; 2023; 14():1139268. PubMed ID: 37575237
[TBL] [Abstract] [Full Text] [Related]
17. A Comprehensive Review of miRNAs and Their Epigenetic Effects in Glioblastoma.
Hasan H; Afzal M; Castresana JS; Shahi MH
Cells; 2023 Jun; 12(12):. PubMed ID: 37371047
[TBL] [Abstract] [Full Text] [Related]
18. BRAFV600 variant allele frequency predicts outcome in metastatic melanoma patients treated with BRAF and MEK inhibitors.
Mandalà M; Palmieri G; Ludovini V; Baglivo S; Marasciulo F; Castiglione F; Gili A; Osella Abate S; Rubatto M; Senetta R; Avallone G; Ribero S; Romano L; Pimpinelli N; de Giorgi V; Roila F; Pisano M; Casula M; Manca A; Sini MC; Massi D; Quaglino P;
J Eur Acad Dermatol Venereol; 2023 Oct; 37(10):1991-1998. PubMed ID: 37335879
[TBL] [Abstract] [Full Text] [Related]
19. Semi-solid MT and APTw CEST-MRI predict clinical outcome of patients with glioma early after radiotherapy.
Kroh F; von Knebel Doeberitz N; Breitling J; Maksimovic S; König L; Adeberg S; Scherer M; Unterberg A; Bendszus M; Wick W; Bachert P; Debus J; Ladd ME; Schlemmer HP; Korzowski A; Goerke S; Paech D
Magn Reson Med; 2023 Oct; 90(4):1569-1581. PubMed ID: 37317562
[TBL] [Abstract] [Full Text] [Related]
20. Prospective assessment of platelet function in patients undergoing elective resection of glioblastoma multiforme.
Leal-Noval SR; Casado M; Palomares C; Narros JL; García-Garmendia JL; Escolar G; Cuenca DX; Görlinger K
Platelets; 2023 Dec; 34(1):2216802. PubMed ID: 37246516
[TBL] [Abstract] [Full Text] [Related]
[Next]
